Literature DB >> 31803812

Co-infection of Newcastle disease virus genotype XIII with low pathogenic avian influenza exacerbates clinical outcome of Newcastle disease in vaccinated layer poultry flocks.

V Gowthaman1,2, S D Singh1, K Dhama1, M A Ramakrishnan3, Y P S Malik4, T R Gopala Krishna Murthy2, R Chitra5, M Munir6.   

Abstract

Newcastle disease (ND) and avian influenza (AI) are economically important infectious diseases of poultry. Sometime, concomitant secondary viral/or bacterial infections significantly alters the pathobiology of ND and AI in poultry. As of now, the disease patterns and dynamics of co-infections caused by ND virus (NDV, genotype XIII) and Low Pathogenic AI viruses (LPAI, H9N2) are explicitly elusive. Thus, we examined the clinicopathological disease conditions due to these two economically important viruses to understand the complex disease outcomes by virus-virus interactions in vaccinated flocks. The findings of clinicopathological and molecular investigations carried on 37 commercial ND vaccinated poultry flocks revealed simultaneous circulation of NDV and AIV in same flock/bird. Further, molecular characterization of hemagglutinin (HA) and neuraminidase (NA) genes confirmed that all the identified AIVs were of low pathogenicity H9N2 subtype and fusion (F) gene analysis of detected NDVs belong to NDV class II, genotype XIII, a virulent type. The NDV and H9N2 alone or co-infected flocks (NDV + LPAI) exhibit clinical signs and lesions similar to that of virulent NDV except the degree of severity, which was higher in H9N2-NDV co-infected flocks. Additionally, avian pathogenic E. coli and mycoplasma infections were detected in majority of the ailing/dead birds from the co-infected flocks during progression of the clinical disease. Overall, the findings highlight the multi-factorial disease complexity in commercial poultry and suggest the importance of NDV genotype XIII in intensifying the clinical disease in vaccinated birds. © Indian Virological Society 2019.

Entities:  

Keywords:  Clinicopathological patterns; E. coli; Low pathogenic avian influenza; Mycoplasma; Newcastle disease; Poultry

Year:  2019        PMID: 31803812      PMCID: PMC6864143          DOI: 10.1007/s13337-019-00533-6

Source DB:  PubMed          Journal:  Virusdisease        ISSN: 2347-3584


  38 in total

1.  Pathotypic and Sequence Characterization of Newcastle Disease Viruses from Vaccinated Chickens Reveals Circulation of Genotype II, IV and XIII and in India.

Authors:  S J Jakhesara; V V S P Prasad; J K Pal; M K Jhala; K S Prajapati; C G Joshi
Journal:  Transbound Emerg Dis       Date:  2014-11-18       Impact factor: 5.005

2.  Ultrastructural changes of the tracheal epithelium after vaccination of day-old chickens with the La Sota strain of Newcastle disease virus.

Authors:  J Mast; C Nanbru; T van den Berg; G Meulemans
Journal:  Vet Pathol       Date:  2005-09       Impact factor: 2.221

3.  Avian influenza H9N2 subtype in Poland--characterization of the isolates and evidence of concomitant infections.

Authors:  Krzysztof Smietanka; Zenon Minta; Edyta Swiętoń; Monika Olszewska; Michał Jóźwiak; Katarzyna Domańska-Blicharz; Krzysztof Wyrostek; Grzegorz Tomczyk; Anna Pikuła
Journal:  Avian Pathol       Date:  2014-10-03       Impact factor: 3.378

4.  Emerging variant of genotype XIII Newcastle disease virus from Northeast India.

Authors:  Barnali Nath; Sachin Kumar
Journal:  Acta Trop       Date:  2017-04-24       Impact factor: 3.112

5.  Role of Staphylococcus protease in the development of influenza pneumonia.

Authors:  M Tashiro; P Ciborowski; H D Klenk; G Pulverer; R Rott
Journal:  Nature       Date:  1987 Feb 5-11       Impact factor: 49.962

6.  Avian influenza (H9N2) outbreak in Iran.

Authors:  H Nili; K Asasi
Journal:  Avian Dis       Date:  2003       Impact factor: 1.577

7.  Co-infection of broilers with Ornithobacterium rhinotracheale and H9N2 avian influenza virus.

Authors:  Qing Pan; Aijing Liu; Faming Zhang; Yong Ling; Changbo Ou; Na Hou; Cheng He
Journal:  BMC Vet Res       Date:  2012-07-02       Impact factor: 2.741

8.  Assessment of methods for amino acid matrix selection and their use on empirical data shows that ad hoc assumptions for choice of matrix are not justified.

Authors:  Thomas M Keane; Christopher J Creevey; Melissa M Pentony; Thomas J Naughton; James O Mclnerney
Journal:  BMC Evol Biol       Date:  2006-03-24       Impact factor: 3.260

9.  Patho-epidemiological study on Genotype-XIII Newcastle disease virus infection in commercial vaccinated layer farms.

Authors:  J H Khorajiya; Sunanda Pandey; Priya D Ghodasara; B P Joshi; K S Prajapati; D J Ghodasara; R A Mathakiya
Journal:  Vet World       Date:  2015-03-21

10.  Coinfection of avian influenza virus (H9N2 subtype) with infectious bronchitis live vaccine.

Authors:  M Haghighat-Jahromi; K Asasi; H Nili; H Dadras; A H Shooshtari
Journal:  Arch Virol       Date:  2008-02-05       Impact factor: 2.574

View more
  3 in total

1.  CAvant® WO-60 as an Effective Immunological Adjuvant for Avian Influenza and Newcastle Disease Vaccine.

Authors:  Eun-Seo Lee; Young-Jung Shim; W A Gayan Chathuranga; Young-Hoon Ahn; In-Joong Yoon; Sung-Sik Yoo; Jong-Soo Lee
Journal:  Front Vet Sci       Date:  2021-12-03

2.  Detection of Newcastle disease virus and assessment of associated relative risk in backyard and commercial poultry in Kerala, India.

Authors:  Chintu Ravishankar; Rajasekhar Ravindran; Anneth Alice John; Nithin Divakar; George Chandy; Vinay Joshi; Deepika Chaudhary; Nitish Bansal; Renu Singh; Niranjana Sahoo; Sunil K Mor; Nand K Mahajan; Sushila Maan; Naresh Jindal; Megan A Schilling; Catherine M Herzog; Saurabh Basu; Jessica Radzio-Basu; Vivek Kapur; Sagar M Goyal
Journal:  Vet Med Sci       Date:  2022-02-24

3.  Novel variant infectious bursal disease virus suppresses Newcastle disease vaccination in broiler and layer chickens.

Authors:  Linjin Fan; Yulong Wang; Nan Jiang; Mango Chen; Li Gao; Kai Li; Yulong Gao; Hongyu Cui; Qing Pan; Changjun Liu; Yanping Zhang; Xiaomei Wang; Xiaole Qi
Journal:  Poult Sci       Date:  2020-09-28       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.